Moderna Provides Update on Norovirus Vaccine Candidate
3 days ago · Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.
Norovirus vaccine from Moderna could have Phase 3 results this …
5 days ago · Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.
From Covid to Norovirus: Moderna’s mRNA Tech Takes on
Jan 20, 2025 · The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase III trial that will test out a vaccine against …
Moderna Announces First Participant Dosed in Pivotal Phase 3 …
Sep 30, 2024 · Norovirus is highly contagious and a leading cause of diarrheal disease globally, associated with 18% of all AGE, 1 resulting in approximately 200,000 deaths per year and …
Moderna says it’s ‘one step closer’ to a norovirus ... - Yahoo
Jan 13, 2025 · Moderna’s Dr. Doran Fink, clinical therapeutic area head for gastrointestinal and bacterial pathogens, sheds light on why an effective norovirus vaccine has proven elusive.
Understanding Norovirus: Staying Safe Amid Winter Surge
5 days ago · At Moderna, we embrace the responsibility to explore mRNA’s full potential in addressing the global burden of Norovirus and are proud to have two vaccine candidates in …
A Norovirus Vaccine Is in the Works | TIME
Jan 10, 2025 · How close are we to having a norovirus vaccine? Moderna is currently enrolling 25,000 people around the world in a phase 3 trial of the shot, after earlier testing showed …
IDWeek 2024: Moderna’s norovirus vaccine mRNA-1403 shows …
Oct 21, 2024 · At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA …
Moderna doses first subject in mRNA norovirus vaccine trial
Oct 1, 2024 · US-based pharmaceutical company Moderna has dosed the first subject in the US in its Phase III Nova 301 clinical trial of its investigational norovirus vaccine, mRNA-1403. The …
Moderna Announces First Participant Dosed in Pivotal Phase 3
Sep 30, 2024 · Moderna, Inc. today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, …